AI Health Index: Clinical Trials AI changes https://aihealthindex.io/categories/clinical-trials-ai Material product changes at Clinical Trials AI vendors, tracked by AI Health Index. Every entry is dated and cited to a public source. en-us Free to reuse with a visible link to aihealthindex.io. Terms: https://aihealthindex.io/use-this-data Thu, 24 Sep 2026 12:00:00 GMT 720 https://aihealthindex.io/icon-192.png AI Health Index: Clinical Trials AI changes https://aihealthindex.io/categories/clinical-trials-ai Edison Scientific: Kosmos can now read licensed full text research from specialist journals across Springer Nature's Nature portfolio when it generates… https://aihealthindex.io/changelog/edison-scientific aihealthindex.io:change:6ab90c10ee3c2977980e6542 Thu, 24 Sep 2026 12:00:00 GMT Product / capability Drug Discovery AI Clinical Trials AI Kosmos can now read licensed full text research from specialist journals across Springer Nature's Nature portfolio when it generates hypotheses or evaluates targets, under a subscription agreement Edison announced on 24 September. Kosmos links each surfaced article to its Version of Record, so outputs reflect corrected versions including retractions and editors' notes. Edison states the Nature portfolio is accessible in Kosmos as of the announcement date and calls it the first of several content partnerships.

Why it matters: R&D teams evaluating an AI scientist need to know which licensed literature grounds its conclusions, and retraction aware Version of Record linking reduces the risk of hypotheses built on withdrawn findings.

Impact: Medium. Verification: Verified. Type: Product / capability.

Evidence: Vendor announcement

Source: AI Health Index change log. Free to reuse with a link back. Terms.

]]> Veeva Systems: Veeva announced Study Builder Agent, which configures Veeva EDC forms, visits and edit checks and Veeva DQS listings directly from a study… https://aihealthindex.io/changelog/veeva-systems aihealthindex.io:change:6ab85e9bd92e5616ac6dc817 Thu, 24 Sep 2026 12:00:00 GMT Product / capability Clinical Trials AI Veeva announced Study Builder Agent, which configures Veeva EDC forms, visits and edit checks and Veeva DQS listings directly from a study protocol, reusing an organization's existing standards and the CDISC USDM model, and generates test data. Veeva says it can bring study configuration down to as little as one day. It is planned for early adopter availability in December 2026, is included in EDC with no additional license, and is delivered as a Claude Cowork plugin.

Why it matters: Study build is one of the slowest steps in trial startup, so the one day claim is worth testing on a real protocol once early adopter access opens. Sponsors should ask which study designs the agent handles and what a person still reviews before a build goes live.

Impact: Medium. Verification: Verified. Type: Product / capability.

Evidence: Vendor announcement

Source: AI Health Index change log. Free to reuse with a link back. Terms.

]]> Insilico Medicine: Insilico announced that Model Context Protocol servers are now available across its Pharma.AI software, so outside AI agents can connect… https://aihealthindex.io/changelog/insilico-medicine aihealthindex.io:change:6ab85e9bd92e5616ac6dc816 Thu, 24 Sep 2026 12:00:00 GMT Product / capability Drug Discovery AI Clinical Trials AI Insilico announced that Model Context Protocol servers are now available across its Pharma.AI software, so outside AI agents can connect directly to its biology, chemistry and biologics engines, including Generative Biologics, PandaOmics and Chemistry42, and run multistep discovery workflows. The announcement previews a 30 September webinar that will present new PandaOmics Agent skills and other platform updates.

Why it matters: MCP access lets a customer's own agents drive Insilico's engines, which turns Pharma.AI from a set of applications into a component of the customer's stack. Teams should ask how data sent through those servers is logged and whether it is used to train Insilico's models.

Impact: Medium. Verification: Verified. Type: Product / capability.

Evidence: Vendor announcement

Source: AI Health Index change log. Free to reuse with a link back. Terms.

]]> Indica Labs: A Voicebrook VoiceOver PRO integration with the HALO AP platform is now available, adding voice control of case and slide navigation… https://aihealthindex.io/changelog/indica-labs aihealthindex.io:change:6ab90c10ee3c2977980e6540 Tue, 22 Sep 2026 12:00:00 GMT EHR / interoperability Digital Pathology AI Diagnostics & Genomics Clinical Trials AI A Voicebrook VoiceOver PRO integration with the HALO AP platform is now available, adding voice control of case and slide navigation (zoom, pan, annotation, tab switching) and voice ordering of stains and AI analyses. A single command pulls HALO Clinical AI biomarker results such as ER and PR percentages into the matching CAP cancer protocol checklist, and sites that report inside HALO AP can pass results through to the LIS.

Why it matters: Labs running HALO Clinical AI no longer need a pathologist to re key biomarker values into the synoptic report, which removes a transcription error point in a clinically weighted field. HALO Clinical AI remains Research Use Only in the US, so automated result capture applies to clinical reporting only where the product is cleared or marked.

Impact: Medium. Verification: Verified. Type: EHR / interoperability.

Evidence: Vendor announcement

Source: AI Health Index change log. Free to reuse with a link back. Terms.

]]> Atropos Health states it expanded its federated Atropos Evidence Network to cover over 330 million U.S. patients, including more than 150… https://aihealthindex.io/changelog/atropos-health aihealthindex.io:change:6ab90c10ee3c2977980e653a Tue, 22 Sep 2026 12:00:00 GMT Product / capability Clinical Reference & Evidence Clinical Trials AI Clinical Decision Support Atropos Health states it expanded its federated Atropos Evidence Network to cover over 330 million U.S. patients, including more than 150 million EHR records with clinical notes, and added imaging and omics data linked to clinical outcomes and mortality through data partners including Norstella, Arcadia and OneMedNet. The network is queried through ChatRWD, Green Button and GENEVA OS, with the Real World Fitness Score grading data quality per question. The company claims temporal queries run up to 50 times faster and 30 times cheaper than traditional analytics; no method for that comparison is published.

Why it matters: Health systems and life sciences teams generating real world evidence can now study questions that need imaging or genomic context alongside EHR and claims data. The speed and cost figures are vendor claims without a stated baseline, so ask for the comparison behind them.

Impact: Medium. Verification: Verified. Type: Product / capability.

Evidence: Vendor announcement

Source: AI Health Index change log. Free to reuse with a link back. Terms.

]]> Deciphex launched CipherX, a pathology AI engine that pairs foundation models with a semantic layer translating their representations into… https://aihealthindex.io/changelog/deciphex aihealthindex.io:change:6ab85e9bd92e5616ac6dc811 Tue, 22 Sep 2026 12:00:00 GMT Model / architecture Digital Pathology AI Drug Discovery AI Clinical Trials AI Deciphex launched CipherX, a pathology AI engine that pairs foundation models with a semantic layer translating their representations into named, pathologist validated tissue signatures. Deciphex states CipherX is in production in its Diagnexia clinical diagnostic service and its Patholytix research business, and reports negative predictive values of 99.85 percent for adenocarcinoma and 98.76 percent for melanoma in production, with every Diagnexia case signed out by a pathologist.

Why it matters: Labs using Diagnexia get CipherX inside the service rather than as a separate purchase. The predictive values are vendor reported, so ask for the case mix and prevalence behind them and which signatures are used in clinical sign out today rather than research only.

Impact: High. Verification: Verified. Type: Model / architecture.

Evidence: Vendor announcement

Source: AI Health Index change log. Free to reuse with a link back. Terms.

]]> Sorcero's Fall 2026 release adds purpose built AI solutions for field medical, medical communications, and therapeutic leadership and… https://aihealthindex.io/changelog/sorcero aihealthindex.io:change:6aaeaddaaaa02078636c9cb3 Tue, 15 Sep 2026 12:00:00 GMT Product / capability Clinical Trials AI Sorcero's Fall 2026 release adds purpose built AI solutions for field medical, medical communications, and therapeutic leadership and launch teams, plus a Medical Strategy solution for tracking scientific resonance. It also introduces Sorcero Wizard, a conversational layer for working with the data, and analytics views that show data ingestion and intelligence generation in real time.

Why it matters: Medical affairs teams work under strict rules about what they can say and to whom, so governance is the feature that matters here. Ask how the platform separates what field medical can see from what commercial teams can see.

Impact: Medium. Verification: Verified. Type: Product / capability.

Evidence: Vendor announcement

Source: AI Health Index change log. Free to reuse with a link back. Terms.

]]> Aignostics released PathoSearch in early access, a visual search engine for pathology: from a screenshot of a region of interest on an H… https://aihealthindex.io/changelog/aignostics aihealthindex.io:change:6aa5b27795f1c7683c18cf6f Sat, 12 Sep 2026 12:00:00 GMT Product / capability Digital Pathology AI Drug Discovery AI Clinical Trials AI Aignostics released PathoSearch in early access, a visual search engine for pathology: from a screenshot of a region of interest on an H and E slide it retrieves morphologically similar, diagnosed reference cases so a pathologist can build a differential in minutes. Search runs on embeddings from Atlas 2, Aignostics' pathology foundation model co developed with Mayo Clinic, against a curated multi center reference set of more than 310,000 whole slide images from over 35,000 cases spanning more than 300 diagnostic entities across 27 organs, covering thoracic, digestive, soft tissue and bone, female genital, and urinary and male genital cancers at launch. The first integration is live inside Techcyte's Fusion AP slide viewer, where a selected region is passed to PathoSearch without export or upload. PathoSearch is free during early access, by waitlist, and is labeled research use only, not for diagnostic procedures.

Why it matters: Rare and complex cases are where a pathologist reaches for a textbook or a paid consult, and image similarity search against a diagnosed reference set is a plausible replacement for the first of those. The research use only label is the operative constraint: this cannot be part of a signed out diagnosis today, and a lab evaluating it should treat the Fusion AP integration as the way to try it inside the workflow rather than as a clinical deployment.

Impact: Medium. Verification: Partially Verified. Type: Product / capability.

Evidence: Vendor announcement

Source: AI Health Index change log. Free to reuse with a link back. Terms.

]]> IQVIA launched Predictive Clinical Development, a suite covering site selection and study design, an automated start up path it calls Push… https://aihealthindex.io/changelog/iqvia aihealthindex.io:change:6a9c312c04c538181acf1b41 Thu, 03 Sep 2026 12:00:00 GMT Product / capability Clinical Trials AI Clinical Decision Support IQVIA launched Predictive Clinical Development, a suite covering site selection and study design, an automated start up path it calls Push Button Start-Up, and real time data cleaning aimed at shortening the gap to database lock.

Why it matters: Each of the three targets a different well known delay, and the one worth interrogating is real time data cleaning, because database lock timelines are usually held up by query resolution rather than by query generation. Sponsors evaluating this should ask which of the three has a measured effect on an actual study rather than a modeled one.

Impact: High. Verification: Verified. Type: Product / capability.

Evidence: Vendor announcement

Source: AI Health Index change log. Free to reuse with a link back. Terms.

]]> Insilico Medicine: Insilico released a set of small language models trained as scientific specialists for chemistry and biology through its MMAI Gym for… https://aihealthindex.io/changelog/insilico-medicine aihealthindex.io:change:6a9c312c04c538181acf1b3a Tue, 01 Sep 2026 12:00:00 GMT Model / architecture Drug Discovery AI Clinical Trials AI Insilico released a set of small language models trained as scientific specialists for chemistry and biology through its MMAI Gym for Science framework. The set covers chemical synthesis, ADMET prediction and potency prediction across GPCR and kinase panels, and includes a single step retrosynthesis model built on Liquid AI's 2.6 billion parameter architecture.

Why it matters: Naming the base architecture and the parameter count is unusual in this category and is the reason this is graded on model transparency rather than capability alone. For discovery teams the practical read is that these are narrow specialists rather than a general assistant, which is the right shape for ADMET and potency work where a confident wrong answer is expensive.

Impact: High. Verification: Verified. Type: Model / architecture.

Evidence: Vendor announcement

Source: AI Health Index change log. Free to reuse with a link back. Terms.

]]> Tempus received FDA 510(k) clearance for Tempus ECG PH, software that reads a standard 12 lead electrocardiogram and identifies signs… https://aihealthindex.io/changelog/tempus aihealthindex.io:change:6a92e5ef75bbcbbe469c6fec Mon, 24 Aug 2026 12:00:00 GMT Regulatory / FDA Clinical Decision Support Diagnostics & Genomics RCM & Prior Auth AI Clinical Trials AI Tempus received FDA 510(k) clearance for Tempus ECG PH, software that reads a standard 12 lead electrocardiogram and identifies signs associated with pulmonary hypertension. The device does not require new hardware or a new test, since it runs against ECGs that are already being captured for other reasons. This adds to the cleared cardiovascular algorithm suite Tempus has been assembling, and pulmonary hypertension is a deliberate target because it is characteristically diagnosed late.

Why it matters: Clearance is the gate that separates a research grade algorithm from something a cardiology service can put into routine practice, and this one runs on data every hospital already has in volume. The deployment question is what happens downstream of a positive flag, because pulmonary hypertension confirmation requires right heart catheterization and a screening tool that raises referral volume without a matching diagnostic pathway creates a bottleneck rather than removing one. Ask for the sensitivity and specificity in the cleared indication and the population it was established in.

Impact: High. Verification: Verified. Type: Regulatory / FDA.

Evidence: Vendor announcement

Source: AI Health Index change log. Free to reuse with a link back. Terms.

]]> Insilico Medicine convened the Open Consortium for Benchmark Quality in AI Driven Drug Discovery, known as O3DC, and published a live… https://aihealthindex.io/changelog/insilico-medicine aihealthindex.io:change:6a92e5ef75bbcbbe469c6fea Mon, 24 Aug 2026 12:00:00 GMT Safety / governance Drug Discovery AI Clinical Trials AI Insilico Medicine convened the Open Consortium for Benchmark Quality in AI Driven Drug Discovery, known as O3DC, and published a live catalog of the benchmarks the field uses to claim performance. The catalog tracks each benchmark's metrics, maintainers and repository activity, and unusually it documents the known caveats, biases and limitations of each one rather than presenting them as neutral yardsticks. The stated premise is that a benchmark with an undisclosed bias produces model comparisons that look rigorous and are not.

Why it matters: Pharmaceutical evaluators comparing AI drug discovery platforms are almost always comparing benchmark scores, and this is the first centralized attempt to say which of those benchmarks can carry the weight. It is worth noting that the vendor convening a benchmark integrity consortium is also a vendor whose own models are scored on those benchmarks, so the catalog is useful and is not disinterested. Read it as a map of where the measurement problems are rather than as an independent audit.

Impact: Medium. Verification: Verified. Type: Safety / governance.

Evidence: Vendor announcement

Source: AI Health Index change log. Free to reuse with a link back. Terms.

]]> Owkin received European regulatory approval for two first-in-class AI diagnostic solutions designed for breast cancer and colorectal cancer. https://aihealthindex.io/changelog/owkin aihealthindex.io:change:6a89d007fbe75a71b1da726b Tue, 18 Aug 2026 12:00:00 GMT Regulatory / FDA Drug Discovery AI Clinical Trials AI Owkin received European regulatory approval for two first-in-class AI diagnostic solutions designed for breast cancer and colorectal cancer. The tools leverage multimodal patient data to assist in biomarker screening and outcome prediction.

Why it matters: European healthcare providers and laboratories can now clinically deploy these validated AI diagnostic tools. This provides pathologists and oncologists with approved decision support for breast and colorectal cancer diagnostics.

Impact: High. Verification: Verified. Type: Regulatory / FDA.

Evidence: Vendor announcement

Source: AI Health Index change log. Free to reuse with a link back. Terms.

]]> 4baseCare launched TARGT Indiegene V2, a cancer profiling panel expanded to cover 2,206 genes. https://aihealthindex.io/changelog/4basecare aihealthindex.io:change:6a89d007fbe75a71b1da7269 Tue, 18 Aug 2026 12:00:00 GMT Product / capability Diagnostics & Genomics Clinical Decision Support Clinical Trials AI 4baseCare launched TARGT Indiegene V2, a cancer profiling panel expanded to cover 2,206 genes. The updated panel is positioned by the vendor as providing precision oncology insights tailored for diverse and historically underrepresented populations.

Why it matters: Oncologists and health systems gain access to a significantly expanded genomic panel, which the vendor positions as enabling more precise targeted therapy selection for cancer patients from diverse genetic backgrounds. Reported only in trade press so far; confirm panel specifications at source before relying on them.

Impact: Medium. Verification: Partially Verified. Type: Product / capability.

Evidence: Trade press

Source: AI Health Index change log. Free to reuse with a link back. Terms.

]]> Indica Labs announced version 4.3 of its HALO, HALO AI, and HALO Link platforms. https://aihealthindex.io/changelog/indica-labs aihealthindex.io:change:6a89d007fbe75a71b1da7268 Mon, 17 Aug 2026 12:00:00 GMT Product / capability Digital Pathology AI Diagnostics & Genomics Clinical Trials AI Indica Labs announced version 4.3 of its HALO, HALO AI, and HALO Link platforms. The release includes a reworked image copy system in HALO for improved workflow flexibility and new features in HALO AI that the vendor says enable more efficient model testing.

Why it matters: Pathology labs and researchers can utilize the updated image management system and enhanced model testing tools to streamline their digital pathology operations and validate AI algorithms more effectively.

Impact: Medium. Verification: Verified. Type: Product / capability.

Evidence: Vendor announcement

Source: AI Health Index change log. Free to reuse with a link back. Terms.

]]> Ochsner Health reported outcomes from deploying Paradigm Health's LLM-based clinical trial recruitment platform across its 47 hospitals… https://aihealthindex.io/changelog/paradigm-health aihealthindex.io:change:6a808db25e3cc8842da0dc3c Thu, 13 Aug 2026 12:00:00 GMT Clinical evidence Clinical Trials AI Clinical Decision Support Ochsner Health reported outcomes from deploying Paradigm Health's LLM-based clinical trial recruitment platform across its 47 hospitals and 370 health centers. The AI-powered system connects to the EHR to continuously evaluate patient records against eligibility criteria, leading to a 41% increase in screening capacity, a 3.6-fold increase in patients identified for future trial eligibility, and a 75% reduction in manual review effort by clinical research coordinators.

Why it matters: Real-world operational metrics from a major health system provide robust evidence that this AI platform can significantly scale clinical trial screening volumes without a proportional increase in headcount. The reported 75% drop in manual effort offers a strong return-on-investment case for research administrators seeking to alleviate coordinator burnout and maximize trial enrollment.

Impact: High. Verification: Partially Verified. Type: Clinical evidence.

Evidence: Trade press

Source: AI Health Index change log. Free to reuse with a link back. Terms.

]]> Proscia received a new FDA 510(k) clearance for its Concentriq AP-Dx digital pathology platform. https://aihealthindex.io/changelog/proscia aihealthindex.io:change:6a7739f386781bb15a7c68dc Thu, 06 Aug 2026 12:00:00 GMT Regulatory / FDA Digital Pathology AI Diagnostics & Genomics Clinical Trials AI Proscia received a new FDA 510(k) clearance for its Concentriq AP-Dx digital pathology platform. The clearance introduces a Predetermined Change Control Plan (PCCP), adds cloud deployment capabilities, and expands interoperability to include the Leica Aperio GT 450 DX slide scanner.

Why it matters: The inclusion of a PCCP allows laboratories to adopt future FDA-cleared scanners and displays without waiting for Proscia to submit additional 510(k) filings. The newly cleared cloud deployment option and expanded scanner compatibility also provide health systems with flexibility in how they implement and scale their digital pathology infrastructure.

Impact: High. Verification: Verified. Type: Regulatory / FDA.

Evidence: Vendor announcement

Source: AI Health Index change log. Free to reuse with a link back. Terms.

]]> Tempus announced the publication of a study in Nature Medicine demonstrating the performance of PRISM2, its multimodal slide-level… https://aihealthindex.io/changelog/tempus aihealthindex.io:change:6a7739f386781bb15a7c68cf Tue, 04 Aug 2026 12:00:00 GMT Clinical evidence Clinical Decision Support Diagnostics & Genomics RCM & Prior Auth AI Clinical Trials AI Tempus announced the publication of a study in Nature Medicine demonstrating the performance of PRISM2, its multimodal slide-level pathology foundation model developed with Microsoft. The model processes routine hematoxylin and eosin slides to predict biomarker status and patient prognosis without requiring specialized fine-tuning.

Why it matters: Clinical buyers and oncology researchers can leverage this peer-reviewed evidence to validate the diagnostic and prognostic accuracy of Tempus's pathology foundation models. The ability to extract deep biological insights from standard slides reduces the need for additional complex assays.

Impact: High. Verification: Verified. Type: Clinical evidence.

Evidence: Vendor announcement

Source: AI Health Index change log. Free to reuse with a link back. Terms.

]]> Insilico Medicine published a collaborative study in npj Precision Oncology demonstrating the use of its PandaOmics AI platform to… https://aihealthindex.io/changelog/insilico-medicine aihealthindex.io:change:6a7739f386781bb15a7c68cc Tue, 04 Aug 2026 12:00:00 GMT Clinical evidence Drug Discovery AI Clinical Trials AI Insilico Medicine published a collaborative study in npj Precision Oncology demonstrating the use of its PandaOmics AI platform to identify therapeutic targets for inverted papilloma-associated sinonasal squamous cell carcinoma. The platform integrated transcriptomic data with pathway biology and protein interaction networks to map the molecular cascade of the disease.

Why it matters: This peer-reviewed publication provides concrete validation of the platform's ability to discover actionable targets in rare and poorly understood cancers. Buyers evaluating the software can use this evidence to assess its utility in complex multi-omic analysis and translational research.

Impact: Medium. Verification: Verified. Type: Clinical evidence.

Evidence: Vendor announcement

Source: AI Health Index change log. Free to reuse with a link back. Terms.

]]> PathAI released version 2.21 of its AISight Dx digital pathology platform, introducing customizable case dashboards, an AI impressions… https://aihealthindex.io/changelog/pathai aihealthindex.io:change:6a6e7c13d9213f7e7baf7ca0 Wed, 29 Jul 2026 12:00:00 GMT Product / capability Digital Pathology AI Clinical Trials AI Diagnostics & Genomics PathAI released version 2.21 of its AISight Dx digital pathology platform, introducing customizable case dashboards, an AI impressions widget, and expanded metadata support for bulk slide ingestion. The update adds support for Amazon S3 Glacier Deep Archive to move older digitized slides to cold storage, along with new slide review tools like editable linear measurements.

Why it matters: Administrators managing enterprise pathology workflows gain improved control over case prioritization and storage costs through the new dashboard and Amazon S3 Glacier archiving capabilities. The expanded metadata ingestion ensures that critical specimen and block identifiers from laboratory information systems are preserved when cases enter the digital viewer.

Impact: Medium. Verification: Partially Verified. Type: Product / capability.

Evidence: Trade press

Source: AI Health Index change log. Free to reuse with a link back. Terms.

]]> Tempus acquired Deep 6 AI in March 2025, adding an AI precision research platform that mines structured and unstructured EMR data to match… https://aihealthindex.io/changelog/tempus aihealthindex.io:change:6a5d560a20eb605b85757c5c Sat, 01 Mar 2025 12:00:00 GMT Acquisition / corporate Clinical Decision Support Diagnostics & Genomics RCM & Prior Auth AI Clinical Trials AI Tempus acquired Deep 6 AI in March 2025, adding an AI precision research platform that mines structured and unstructured EMR data to match patients to clinical trials and generate real world evidence. Deep 6 continues to operate under its own name and reports real time EMR feeds across more than 30 health systems and an ecosystem of over 1,000 research facilities. This index records the capability inside the Tempus vendor entry rather than as a separate record, consistent with how other acquired product lines are handled.

Why it matters: For a health system already running Tempus Next or Hub, this quietly widens what the relationship covers: the same vendor now sits on clinical decision support, prior authorization, and trial recruitment, all reading the same EMR. That consolidation is convenient and worth scrutinizing, since the data access granted for one purpose now serves several. The technically interesting claim is about unstructured data: Deep 6 reports that 92 percent of trial inclusion and exclusion criteria benefit from unstructured sources and that 15 to 20 percent of eligible patients are found through free text alone, which is the actual argument for NLP based matching over coded data queries. Two things to establish: that data ownership remains with the health system rather than transferring with the platform, and that matched cohorts are treated as decision support requiring validation, which the company itself states.

Impact: Medium. Verification: Verified. Type: Acquisition / corporate.

Evidence: Vendor announcement

Source: AI Health Index change log. Free to reuse with a link back. Terms.

]]>